Trial Profile

Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atoltivimab/maftivimab/odesivimab (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
Indications Ebola virus infections
Focus Therapeutic Use
Acronyms EBO-PEP

Most Recent Events

22 Jan 2026 Planned initiation date changed from 1 Oct 2025 to 1 Sep 2026.
08 Oct 2025 Planned End Date changed from 1 Dec 2027 to 1 Aug 2028.
08 Oct 2025 Planned primary completion date changed from 1 Jun 2027 to 1 Aug 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com